Dupilumab for atopic dermatitis treatment: A single-center retrospective study


Creative Commons License

YAŞAR SUBAŞI G., BİLGİÇ A., YILMAZ E.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, vol.56, no.1, pp.12-16, 2022 (ESCI) identifier

Abstract

Background and Design: Atopic dermatitis (AD) is a common chronic, recurrent, and itchy inflammatory skin disease. Various therapeutic agents are available, but severe side effects may limit their usage. Recently, dupilumab, a human monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit of heterodimeric IL-4 and IL-13 receptors, is approved and might be used in patients with resistant AD, with the permission of the Ministry of Health.